{
  "id": 14003832,
  "title": "AstraZeneca at ASBMR 2026: rare disease push hinges on new bone drug",
  "url": "https://urgent.news/2026/10/12/astrazeneca-at-asbmr-2026-rare-disease-push-hinges-on-new-bone-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-12T16:49:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/astrazeneca-at-asbmr-2026-rare-disease-push-hinges-on-new-bone-drug-93CH-4944975"
  },
  "original_language": "en",
  "account": "On October 12, 2026, AstraZeneca (AZN) utilized its AZN Management Meet event in Boston to unveil efzimfotase alfa, a novel enzyme replacement therapy for hypophosphatasia. The company showcased significant improvements in pain, fatigue, and functionality, although the primary walking test did not meet statistical significance in the overall group. The data underscore a broader commercial potential, bolstered by simplified dosing and fewer injection site reactions compared to the existing treatment, Strensiq. Regulatory authorities will need to balance a mixed overall outcome with positive results across age groups and disease types. While efzimfotase alfa failed to meet the primary endpoint in the HICKORY study, secondary measures such as pain, fatigue, and treatment satisfaction were favorable. The drug was engineered for ease of use, with dosing every two weeks and approximately 12 times fewer injections annually. Injection site reactions were also 5 times lower than with Strensiq. AZN maintained peak sales guidance between $3 billion and $5 billion, with an addressable market of around 14,000 patients across the top eight markets. Analysts questioned the FDA's perspective on adult data and the disease's potential treatment as a single condition across all age groups. The company remains confident that efzimfotase alfa is one of its most crucial rare disease assets and reiterated its peak year sales guidance.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}